• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300705.SZ
Share

Hunan Jiudian Pharmaceutical Co., Ltd. Stocks

CN¥ 10.53Last Updated 13.07.2026

Issuer Rating

4/7
Performance

Excellent

Risk

High

Recommendation

Hold

Market Cap

CN¥ 768.60M

CN¥ 10.53
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hunan Jiudian Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise that spans the entire value chain from drug discovery and development to manufacturing and commercialization. The company's extensive product line includes medications for treating allergies, infections, and inflammatory conditions, as well as analgesics and gynecological remedies. Their offerings further extend to products for digestive health, both Western chemical drugs and traditional Chinese patent medicines, medical equipment, and Active Pharmaceutical Ingredients (APIs). Additionally, Hunan Jiudian provides contract manufacturing services for various pharmaceutical formulations, such as tablets, capsules, granules, and oral liquid preparations like solutions and syrups. The company is headquartered in Changsha, China.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 07:30

Jefferies recommended buying shares of Hoka's parent company. The brand could replicate UGG's success.

14.07.2026 02:42

Prosecutors from 12 U.S. states have filed a lawsuit against the Paramount-Warner Bros. Discovery deal

14.07.2026 01:22

SK Hynix Led the Decline Among Chipmakers; Oil Prices Suffered Their Sharpest One-Day Drop Since 2020

14.07.2026 00:44

Oil prices jumped by nearly 10%. The price of Brent crude exceeded $83 per barrel

14.07.2026 00:19

The top-performing stock in the S&P 500 has risen 600% this year. Evercore expects it to rise another 80%.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026